All News

GeneTherapyLive’s Weekly Rewind – November 26, 2021

Review top news and interview highlights from the week ending November 26, 2021.

Developing Gene Therapies for Indications With Unmet Needs

The chief executive and scientific officers of Lysogene discussed Lysogene’s patient-focused therapy development.

CD19+ B-Cell Malignancy Cell Therapy Receives RMAT Designation

In 26 patients with LBCL followed for at least 28 days, the objective response rate (ORR) was 58% with complete responses (CRs) in 38% of patients.